BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qi X, Zhao Y, Li H, Guo X, Han G. Management of hepatocellular carcinoma: an overview of major findings from meta-analyses. Oncotarget 2016;7:34703-51. [PMID: 27167195 DOI: 10.18632/oncotarget.9157] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 8.2] [Reference Citation Analysis]
Number Citing Articles
1 Sun Y, Zhang H, Zhu H, Wu C, Chen M, Han J. A systematic review and meta-analysis comparing tumor progression and complications between radiofrequency ablation and thyroidectomy for papillary thyroid carcinoma. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.994728] [Reference Citation Analysis]
2 Yang P, Li N. Efficacy of percutaneous ethanol injection versus radiofrequency ablation for single hepatocellular carcinoma no larger than 5 cm. J Int Med Res 2022;50:3000605221111281. [PMID: 35861264 DOI: 10.1177/03000605221111281] [Reference Citation Analysis]
3 Vardar BU, Meram E, Karaoglu K, Liang M, Yu M, Laeseke P, Ozkan OS. Radioembolization Followed by Transarterial Chemoembolization in Hepatocellular Carcinoma. Cureus. [DOI: 10.7759/cureus.23783] [Reference Citation Analysis]
4 Schöning W, Raschzok N, Schmelzle M, Pratschke J. Leber – der Leberrundherd. Allgemein- und Viszeralchirurgie II 2022. [DOI: 10.1016/b978-3-437-24812-2.00017-2] [Reference Citation Analysis]
5 Suh YJ, Jin YJ, Jeong Y, Shin WY, Lee JM, Cho S, Yu JH, Lee JW. Resection or ablation versus transarterial therapy for Child-Pugh A patients with a single small hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e27470. [PMID: 34713824 DOI: 10.1097/MD.0000000000027470] [Reference Citation Analysis]
6 Tan CP, Sinigaglia L, Gomez V, Nicholls J, Habib NA. RNA Activation-A Novel Approach to Therapeutically Upregulate Gene Transcription. Molecules 2021;26:6530. [PMID: 34770939 DOI: 10.3390/molecules26216530] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Senk K, Wilcke J, Haimerl M, Verloh N, Rio Bartulos C, Bäumler W, Stroszczynski C, Wiggermann P. Prediction of transarterial chemoembolization (TACE) outcome by pre- and postinterventional 13C-methacetin breath test. Clin Hemorheol Microcirc 2021;79:73-80. [PMID: 34487035 DOI: 10.3233/CH-219118] [Reference Citation Analysis]
8 Huang KW, Tan CP, Reebye V, Chee CE, Zacharoulis D, Habib R, Blakey DC, Rossi JJ, Habib N, Sodergren MH. MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models. Int J Mol Sci 2021;22:9168. [PMID: 34502076 DOI: 10.3390/ijms22179168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
9 Aly A, Lingohr-Smith M, Lin J, Seal B. Locoregional therapy patterns and healthcare economic burden of patients with hepatocellular carcinoma in the USA. Hepat Oncol 2021;8:HEP37. [PMID: 34408847 DOI: 10.2217/hep-2021-0001] [Reference Citation Analysis]
10 Ward EM, Sherif AE, O'Neill S, Hughes M, Ireland H, Wigmore SJ, Adair A. Clinical Outcomes of Ablation Compared with Resection for Single Hepatocellular Carcinoma Lesions, as a Primary Treatment or Bridging to Liver Transplantation: A Retrospective Comparative Study. Ann Transplant 2021;26:e931980. [PMID: 34326301 DOI: 10.12659/AOT.931980] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chen QF, Li W, Yu SC, Chou YH, Rhim H, Yang X, Shen L, Dong A, Huang T, Huang J, Zhang F, Fan W, Zhao M, Gu Y, Huang Z, Zuo M, Zhai B, Xiao Y, Kuang M, Li J, Han J, Song W, Ma J, Wu P. Consensus of Minimally Invasive and Multidisciplinary Comprehensive Treatment for Hepatocellular Carcinoma - 2020 Guangzhou Recommendations. Front Oncol 2021;11:621834. [PMID: 34277397 DOI: 10.3389/fonc.2021.621834] [Reference Citation Analysis]
12 Zhu M, Li H, Wang C, Yang B, Wang X, Hou F, Yang S, Wang Y, Guo X, Qi X. Focal nodular hyperplasia mimicking hepatocellular adenoma and carcinoma in two cases. Drug Discov Ther 2021;15:112-7. [PMID: 33952777 DOI: 10.5582/ddt.2021.01033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Chen L, Ren Y, Sun T, Cao Y, Yan L, Zhang W, Ouyang T, Zheng C. The efficacy of radiofrequency ablation versus cryoablation in the treatment of single hepatocellular carcinoma: A population-based study. Cancer Med 2021;10:3715-25. [PMID: 33960697 DOI: 10.1002/cam4.3923] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Kawanami GH, Katsuda L, Rocha TB, da Silva Yamashiro F, Pelafsky L, Qi X, Romeiro FG. How Much Time Should Be Waited and What Are the Main Findings to Evaluate the Hepatocellular Carcinoma Response to Regorafenib? A Real-Life Experience. Can J Gastroenterol Hepatol 2021;2021:6219896. [PMID: 33614533 DOI: 10.1155/2021/6219896] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Zeng T, Tang Z, Liang L, Suo D, Li L, Li J, Yuan Y, Guan XY, Li Y. PDSS2-Del2, a new variant of PDSS2, promotes tumor cell metastasis and angiogenesis in hepatocellular carcinoma via activating NF-κB. Mol Oncol 2020;14:3184-97. [PMID: 33064899 DOI: 10.1002/1878-0261.12826] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
16 Zhang Q, Zhou K, Liang W, Xiong W. Prognostic and clinicopathological significance of PD-1 expression in hepatocellular carcinoma: a meta-analysis. J Int Med Res 2020;48:300060520962675. [PMID: 33100077 DOI: 10.1177/0300060520962675] [Reference Citation Analysis]
17 Kobe A, Kindler Y, Klotz E, Puippe G, Messmer F, Alkadhi H, Pfammatter T. Fusion of Preinterventional MR Imaging With Liver Perfusion CT After RFA of Hepatocellular Carcinoma: Early Quantitative Prediction of Local Recurrence. Invest Radiol 2021;56:188-96. [PMID: 32932379 DOI: 10.1097/RLI.0000000000000726] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Abdallah MA, Wongjarupong N, Hassan MA, Taha W, Abdalla A, Bampoh S, Onyirioha K, Nelson M, Glubranson LA, Wiseman GA, Fleming CJ, Andrews JC, Mahipal A, Roberts LR. The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study. Expert Rev Gastroenterol Hepatol 2020;14:619-29. [PMID: 32490691 DOI: 10.1080/17474124.2020.1777856] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
19 Purich K, Dang JT, Poonja A, Sun WYL, Bigam D, Birch D, Karmali S. Intraoperative fluorescence imaging with indocyanine green in hepatic resection for malignancy: a systematic review and meta-analysis of diagnostic test accuracy studies. Surg Endosc 2020;34:2891-903. [DOI: 10.1007/s00464-020-07543-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
20 Greten TF. Treatment of Liver Cancer. The Liver 2020. [DOI: 10.1002/9781119436812.ch61] [Reference Citation Analysis]
21 Wang F, Zhang B, Xu X, Zhu L, Zhu X. TRIP6 promotes tumorigenic capability through regulating FOXC1 in hepatocellular carcinoma. Pathol Res Pract 2020;216:152850. [PMID: 32046874 DOI: 10.1016/j.prp.2020.152850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
22 Roth GS, Teyssier Y, Abousalihac M, Seigneurin A, Ghelfi J, Sengel C, Decaens T. Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma. World J Gastroenterol 2020; 26(3): 324-334 [PMID: 31988592 DOI: 10.3748/wjg.v26.i3.324] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
23 Huang Z, Gu Y, Wu S, Lai C, Wang X, Huang J. Computed tomography-guided radiofrequency ablation of the retained iodized oil after simultaneous combination with transarterial embolization in small recurrent or residual hepatocellular carcinoma. J Interv Med 2020;3:49-54. [PMID: 34805907 DOI: 10.1016/j.jimed.2020.01.008] [Reference Citation Analysis]
24 De Raffele E. Liver Cancer. Liver Diseases 2020. [DOI: 10.1007/978-3-030-24432-3_31] [Reference Citation Analysis]
25 Lee J, Gangi A. Regional Therapies in Hepatocellular Carcinoma and Cholangiocarcinoma. Cancer Regional Therapy 2020. [DOI: 10.1007/978-3-030-28891-4_26] [Reference Citation Analysis]
26 Lv T, Kong LX, Yang J, Wu H, Wen T, Jiang L, Yang J. Successful use of the left portal vein as graft for middle hepatic vein reconstruction in left hemihepatectomy: preliminary experience on six cases. World J Surg Oncol 2019;17:187. [PMID: 31706343 DOI: 10.1186/s12957-019-1719-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
27 Taylor AC, Maddirela D, White SB. Role of Radioembolization for Biliary Tract and Primary Liver Cancer. Surgical Oncology Clinics of North America 2019;28:731-43. [DOI: 10.1016/j.soc.2019.07.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
28 Zhou C, Zhang X, Peng Y, Zhou K, Hu J, Yu L, Chen F, Qiu S, Zhou J, Fan J, Zhang L, Wang Z. Surgical Resection plus Radiofrequency Ablation versus Radical Surgery for Hepatocellular Carcinoma: A Propensity Score Matching Analysis. J Cancer 2019;10:3933-40. [PMID: 31417637 DOI: 10.7150/jca.29501] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Neureiter D, Stintzing S, Kiesslich T, Ocker M. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. World J Gastroenterol 2019; 25(25): 3136-3150 [PMID: 31333307 DOI: 10.3748/wjg.v25.i25.3136] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 42] [Article Influence: 12.3] [Reference Citation Analysis]
30 Han B, Li C, Meng H, Gomes Romeiro F, Mancuso A, Zhou Z, Levi Sandri GB, Xu Y, Han T, Han L, Shao L, Qi X. Efficacy and safety of external-beam radiation therapy for hepatocellular carcinoma: An overview of current evidence according to the different target population. Biosci Trends 2019;13:10-22. [PMID: 30799321 DOI: 10.5582/bst.2018.01261] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
31 Jiang S, Wang Z, Ou M, Pang Q, Fan D, Cui P. Laparoscopic Versus Open Hepatectomy in Short- and Long-Term Outcomes of the Hepatocellular Carcinoma Patients with Cirrhosis: A Systematic Review and Meta-Analysis. J Laparoendosc Adv Surg Tech A. 2019;29:643-654. [PMID: 30702362 DOI: 10.1089/lap.2018.0588] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
32 Hashimoto D, Arima K, Nakagawa S, Negoro Y, Hirata T, Hirota M, Inomata M, Fukuzawa K, Ohga T, Saeki H, Oki E, Yamashita YI, Chikamoto A, Baba H, Maehara Y. Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer. J Gastroenterol 2019;54:437-48. [PMID: 30515563 DOI: 10.1007/s00535-018-01535-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
33 Zheng H, Yang Y, Ye C, Li PP, Wang ZG, Xing H, Ren H, Zhou WP. Lamp2 inhibits epithelial-mesenchymal transition by suppressing Snail expression in HCC. Oncotarget 2018;9:30240-52. [PMID: 30100986 DOI: 10.18632/oncotarget.25367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 3722] [Cited by in F6Publishing: 3826] [Article Influence: 930.5] [Reference Citation Analysis]
35 Kis B, El-Haddad G, Sheth RA, Parikh NS, Ganguli S, Shyn PB, Choi J, Brown KT. Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control 2017;24:1073274817729244. [PMID: 28975829 DOI: 10.1177/1073274817729244] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
36 Ying L, Cheng H, Xiong XW, Yuan L, Peng ZH, Wen ZW, Ka LJ, Xiao X, Jing C, Qian TY, Liang GZ, Mei YG, Bo ZW, Liang P. Interferon alpha antagonizes the anti-hepatoma activity of the oncolytic virus M1 by stimulating anti-viral immunity. Oncotarget 2017;8:24694-705. [PMID: 28445966 DOI: 10.18632/oncotarget.15788] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
37 Qi X, Liu Y, Wang W, Cai D, Li W, Hui J, Liu C, Zhao Y, Li G. Management of advanced gastric cancer: An overview of major findings from meta-analysis. Oncotarget. 2016;7:78180-78205. [PMID: 27655725 DOI: 10.18632/oncotarget.12102] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
38 Lang SA, Fichtner-feigl S. Maligne Lebertumoren. Evidenzbasierte Chirurgie 2018. [DOI: 10.1007/978-3-662-56533-9_5] [Reference Citation Analysis]
39 Bilbao JI, Páramo M, Madrid JM, Benito A. Hepatocellular carcinoma treatment: ablation and arterial embolization. Radiologia (Engl Ed) 2018;60:156-66. [PMID: 29108656 DOI: 10.1016/j.rx.2017.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
40 Hashimoto D, Chikamoto A, Masuda T, Nakagawa S, Imai K, Yamashita YI, Reber HA, Baba H. Pancreatic Cancer Arising From the Remnant Pancreas: Is It a Local Recurrence or New Primary Lesion? Pancreas 2017;46:1083-90. [PMID: 28902776 DOI: 10.1097/MPA.0000000000000897] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
41 Katsanos K, Kitrou P, Spiliopoulos S, Maroulis I, Petsas T, Karnabatidis D. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. PLoS One. 2017;12:e0184597. [PMID: 28934265 DOI: 10.1371/journal.pone.0184597] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 13.2] [Reference Citation Analysis]
42 Berretta M, Cavaliere C, Alessandrini L, Stanzione B, Facchini G, Balestreri L, Perin T, Canzonieri V. Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. Oncotarget. 2017;8:14192-14220. [PMID: 28077782 DOI: 10.18632/oncotarget.13929] [Cited by in Crossref: 44] [Cited by in F6Publishing: 51] [Article Influence: 8.8] [Reference Citation Analysis]
43 Chang L, Wang Y, Zhang J, Guo T. The best strategy for HCC patients at each BCLC stage: a network meta-analysis of observational studies. Oncotarget 2017;8:20418-27. [PMID: 28099898 DOI: 10.18632/oncotarget.14668] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
44 Li C, Liu JY, Peng W, Wen TF, Yan LN, Yang JY, Li B, Wang WT, Xu MQ. Liver resection versus transplantation for multiple hepatocellular carcinoma: a propensity score analysis. Oncotarget 2017;8:81492-500. [PMID: 29113408 DOI: 10.18632/oncotarget.20623] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
45 Xie H, Yu H, Tian S, Yang X, Wang X, Yang Z, Wang H, Guo Z. What is the best combination treatment with transarterial chemoembolization of unresectable hepatocellular carcinoma? a systematic review and network meta-analysis. Oncotarget 2017;8:100508-23. [PMID: 29245997 DOI: 10.18632/oncotarget.20119] [Cited by in Crossref: 18] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
46 Gaba RC, Lokken RP, Hickey RM, Lipnik AJ, Lewandowski RJ, Salem R, Brown DB, Walker TG, Silberzweig JE, Baerlocher MO, Echenique AM, Midia M, Mitchell JW, Padia SA, Ganguli S, Ward TJ, Weinstein JL, Nikolic B, Dariushnia SR; Society of Interventional Radiology Standards of Practice Committee. Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. J Vasc Interv Radiol 2017;28:1210-1223.e3. [PMID: 28669744 DOI: 10.1016/j.jvir.2017.04.025] [Cited by in Crossref: 69] [Cited by in F6Publishing: 74] [Article Influence: 13.8] [Reference Citation Analysis]
47 Hao MZ, Lin HL, Chen QZ, Hu YB, Chen JB, Zheng JX, Zhou D, Zhang H. Safety and efficacy of transcatheter arterial chemoembolization with embospheres in treatment of hepatocellular carcinoma. J Dig Dis 2017;18:31-9. [PMID: 27987344 DOI: 10.1111/1751-2980.12435] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
48 Wu B, Zhou Y, Wang Y, Yang XM, Liu ZY, Li JH, Feng F, Chen ZN, Jiang JL. Dominant Suppression of β1 Integrin by Ectopic CD98-ICD Inhibits Hepatocellular Carcinoma Progression. Int J Mol Sci 2016;17:E1882. [PMID: 27834933 DOI: 10.3390/ijms17111882] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]